miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma

Sunitinib is a multitargeting tyrosine kinase inhibitor used for metastatic renal cancer. There are no biomarkers that can predict sunitinib response. Such markers are needed to avoid administration of costly medication with side effects to patients who would not benefit from it. We compared global...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Ther
Main Authors: Khella, Heba W Z, Butz, Henriett, Ding, Qiang, Rotondo, Fabio, Evans, Kenneth R, Kupchak, Peter, Dharsee, Moyez, Latif, Ashraf, Pasic, Maria D, Lianidou, Evi, Bjarnason, Georg A, Yousef, George M
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2015
Fag:
Original Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4817948/
https://ncbi.nlm.nih.gov/pubmed/26201448
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/mt.2015.129
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker